Phase III study evaluating palbociclib (PD-0332991), aCyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
Primary Objective: To compare invasive disease free survival (iDFS) for palbociclib vs. placebo
in patients with residual invasive breast cancer and high CPS-EG score - after neoadjuvant chemotherapy receiving standard adjuvant endocrine therapy for HR-positive/HER2-normal primary breast cancer.
Patient Population: Hormone-receptor-positive / HER2-normal primary breast cancer patients without pathological complete response after neoadjuvant chemotherapy
Target Accrual: 1,100 patients
Status: Active, not recruiting
ClinicalTrials.gov Identifier: NCT01864746
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402